Genzyme to buy AnorMed
October 17, 2006 09:40 AM
E-mail|
|Comments
()|
Text size
–
+
Genzyme Corp. and AnorMed Inc. said today that they struck a deal for Genzyme to buy AnorMed for $580 million, giving it a late-stage drug candidate for stem-cell transplantation.
Genzyme would acquire AnorMed at $13.50 per outstanding share.
Earlier, Millennium Pharmaceuticals Inc. said it would not raise its $515 million bid for AnorMed, paving the way for a new bidder. (AP)
Comment
Permalink
E-mail
